Update from Novo Nordisk regarding its share repurchase programme

NewsGuard 100/100 Score

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 9 November 2009, the following transactions have been made under the programme:

Number of Average Transaction value, shares purchase price DKK Accumulated, last announcement 5,089,099 1,625,077,813 9 November 2009 75,000 323.2516 24,243,870 10 November 2009 75,000 321.9600 24,147,000 11 November 2009 75,000 324.9821 24,373,658 12 November 2009 75,000 326.2050 24,465,375 13 November 2009 75,000 326.5990 24,494,925 Accumulated under the programme 5,464,099 1,746,802,641

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 33,500 B shares in the period from 9 November 2009 to 13 November 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 30,180,477 treasury shares, corresponding to 4.9% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

SOURCE: Novo Nordisk A/S

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.